Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer

International Journal of Oncology

Volumn 40, Issue 6, 2012, Pages 2097-2103

  Weissmann Brenner, Alina ^a,b   Kushnir, Michal ^c   Yanai, Gila Lithwick ^c   Aharonov, Ranit ^c   Gibori, Hadas ^c   Purim, Ofer ^a,b   Kundel, Yulia ^a,b   Morgenstern, Sara ^a,b   Halperin, Marissa ^a,b   Niv, Yaron ^a,b   Brenner, Baruch ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ROSETTA GENOMICS LTD   (Israel)

Author keywords

Colon cancer; microRNA; Prognostic factors

Indexed keywords

MICRORNA 29A;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COLON CANCER; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; RNA EXTRACTION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 84861778203     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1403     Document Type: Article

References (40)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Green FL: Colon and rectum. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th edition. Lippincott-Raven, Philadelphia, PA, 2002.
3. Compton CC, Fielding LP, Burgart LJ, et al: Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 979-994, 2000. (Pubitemid 30602039)
4. Kerr D, Gray R, Quirke P, et al: A quantitative multi-gene RT-qPCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in 4 large studies and results from the independent, prospectively-defined QUASAR calidation study. J Clin Oncol 27: 15s, 2009.
5. Bentwich I, Avniel A, Karov Y, et al: Identification of hundreds of conserved and nonconserved human microRNAs. Nat Gen 37: 766-770, 2005. (Pubitemid 41754896)
6. Farh KK, Grimson A, Jan C, et al: The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science 310: 1817-1821, 2005. (Pubitemid 41814382)
7. Negrini M, Ferracin M, Sabbioni S and Croce CM: microRNAs in human cancer: from research to therapy. J Cell Sci 120: 1833-1840, 2007. (Pubitemid 46979774)
8. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006. (Pubitemid 44629897)
9. Ahmed FE: Role of miRNA in carcinogenesis and biomarker selection: a methodological view. Expert Rev Mol Diagn 7: 569-603, 2007.
10. Nass D, Rosenwald S, Meiri E, et al: miR-92b and miR-9/9*are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol 19: 375-383, 2009.
11. Rosenfeld N, Aharonov R, Meiri E, et al: MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26: 462-469, 2008. (Pubitemid 351501813)
12. Brendle A, Lei H, Brandt A, et al: Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis 29: 1394-1399, 2008.
13. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 54: 1696-1704, 2008.
14. Hu X, Macdonald DM, Huettner PC, et al: A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 14: 457-464, 2009.
15. Langer C, Marcucci G, Holland KB, et al: Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 27: 3198-3204, 2009.
16. Wei JS, Johansson P, Chen QR, et al: microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 15: 5560-5568, 2009.
17. Brenner B, Hoshen M, Purim O, et al: MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol 17: 3976-3985, 2011.
18. Schetter AJ, Leung SY, Sohn JJ, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425-436, 2008. (Pubitemid 351185951)
19. Schepeler T, Reinert JT, Ostenfeld MS, et al: Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 68: 6416-6424, 2008.
20. Díaz R, Silva J, García JM, et al: Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer 47: 794-802, 2008.
21. Xi Y, Formentini A, Chien M, et al: Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2: 113-121, 2006.
22. Gilad S, Meiri E, Yogev Y, et al: Serum microRNAs are promising novel biomarkers. PLoS One 3: e3148, 2008.
23. Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 57: 289-300, 1995.
24. Huang Z, Huang D, Ni S, Peng Z, Sheng W and Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127: 118-126, 2010.
25. Link A, Balaguer F, Shen Y et al: Fecal microRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 19: 1766-1774, 2010.
26. Nakajima G, Hayashi K, Xi Y, et al: Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 3: 317-324, 2006. (Pubitemid 44701551)
27. Zhang W, Winder T, Ning Y, et al: A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 22: 104-109, 2011.
28. Slaby O, Svoboda M, Fabian P, et al: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinico-pathologic features of colorectal cancer. Oncology 72: 397-402, 2007. (Pubitemid 351238155)
29. Kulda V, Pesta M, Topolcan O, et al: Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet 200: 154-160, 2010.
30. Wang CJ, Zhou ZG, Wang L, et al: Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers 26: 27-34, 2009.
31. Motoyama K, Inoue H, Takatsuno Y, et al: Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 34: 1069-1075, 2009.
32. Slattery ML, Wolff E, Hoffman MD, Pellatt DF, Milash B and Wolff RK: MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer 50: 196-206, 2011.
33. Kapinas K, Kessler C, Ricks T, Gronowicz G and Delany AM: miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem 285: 25221-25231, 2010.
34. Fre S, Pallavi SK, Huyghe M, et al: Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc Natl Acad Sci USA 106: 6309-6314, 2009.
35. Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW and Fernandez-Zapico ME: Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem 110: 1155-1164, 2010.
36. Kong G, Zhang J, Zhang S, Shan C, Ye L and Zhang X: Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS One 6: e19518, 2011.
37. Park SY, Lee JH, Ha M, Nam JW and Kim VN: miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 16: 23-29, 2009.
38. Lang N, Liu M, Tang QL, Chen X, Liu Z and Bi F: Effects of microRNA-29 family members on proliferation and invasion of gastric cancer cell lines. Chin J Cancer 29: 603-610, 2010.
39. Muniyappa MK, Dowling P, Henry M, et al: MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. Eur J Cancer 45: 3104-3118, 2009.
40. Han YC, Park CY, Bhagat G, et al: microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med 207: 475-489, 2010.